Form 4: Generation Bio Director Sells Shares Post-Merger

Anthony G. Quinn, a director at Generation Bio Co., reported the disposition of all his direct and indirect common stock and stock options following the company's merger with XOMA Royalty Corporation.

Summary

• Anthony G. Quinn, a director of Generation Bio Co., reported changes in his beneficial ownership following the merger of Generation Bio Co. with XOMA Royalty Corporation.
• The merger, effective February 9, 2026, resulted in Generation Bio Co. becoming a wholly-owned subsidiary of XOMA Royalty Corporation.
• Shareholders received $4.2913 in cash per share plus one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent consideration of $25.01 per CVR.
• Quinn disposed of 29,928 shares of common stock held directly and 7,283 shares held indirectly through the Quinn Family Irrevocable Trust of 2021.
• In-the-money stock options (exercise price less than $4.2913) were converted into cash. Quinn disposed of 3,000 such options with an exercise price of $3.874.
• Out-of-the-money stock options (exercise price equal to or greater than $4.2913) were cancelled for no consideration. Quinn disposed of 5,200 options at $190, 1,500 at $265.9, 1,920 at $61.9, 2,500 at $48.3, and 6,000 at $33.2.
• Following these transactions, Quinn beneficially owns 0 shares of common stock and 0 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive outcome for Generation Bio Co. shareholders who tendered their shares, as they received immediate cash and potential future upside via CVRs. However, the cancellation of out-of-money options is a negative for those specific option holders.

Positives

• Shareholders received a cash payment of $4.2913 per share, providing immediate liquidity.
• Shareholders also received a Contingent Value Right (CVR) with an estimated maximum contingent consideration of $25.01 per CVR, offering potential future upside.
• In-the-money stock options were converted into cash, allowing option holders to realize value.

Negatives

• Generation Bio Co. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of XOMA Royalty Corporation.
• Out-of-the-money stock options were cancelled for no consideration, resulting in a loss of potential value for those option holders.
• The CVR is non-tradeable, limiting liquidity and immediate valuation for the contingent consideration.

Risks

• The value of the Contingent Value Right (CVR) is uncertain and dependent on future events, with an estimated maximum contingent consideration, implying it could be less or zero.

Future Outlook

The filing indicates the completion of the merger, with Generation Bio Co. now operating as a wholly-owned subsidiary of XOMA Royalty Corporation. Future financial performance and strategic direction will be determined by the parent company, with potential contingent payments tied to the CVRs.

Industry Context

StockSavvy.ai notes that this merger represents a consolidation within the biotechnology or pharmaceutical sector, where larger entities often acquire smaller, innovative companies to expand their pipeline or technology portfolio. The use of CVRs is a common mechanism in biotech acquisitions to bridge valuation gaps and share future risks/rewards, particularly for assets in clinical development.

Related Party Transactions

• Anthony G. Quinn, a director of Generation Bio Co., disposed of shares held indirectly through the Quinn Family Irrevocable Trust of 2021, where he is the settlor and his family members are beneficiaries.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, ending their direct ownership in a publicly traded Generation Bio Co.
• Employees (with options): Those with in-the-money options received cash, while those with out-of-the-money options had them cancelled for no value.
• Generation Bio Co. as an entity: Now operates as a private, wholly-owned subsidiary, with strategic decisions made by XOMA Royalty Corporation.

Next Steps

• Shareholders holding CVRs will await future events that trigger contingent payments, as defined by the contingent value rights agreement.
• Generation Bio Co. will operate as a wholly-owned subsidiary of XOMA Royalty Corporation.

Key Dates

Keywords

Generation Bio Co., GBIO, XOMA Royalty Corporation, Merger, Tender Offer, Contingent Value Right, CVR, Insider Trading, Form 4, Beneficial Ownership, Stock Options, Acquisition